Syndax Pharmaceuticals (SNDX) 3rd Annual Guggenheim Healthcare Innovation Conference summary
Event summary combining transcript, slides, and related documents.
3rd Annual Guggenheim Healthcare Innovation Conference summary
11 Nov, 2026Commercial performance
Latest-quarter revenue was $61 million for Revuforj; revenue growth was 11% for Revuforj and 12% for Niktimvo.
Revuforj leads new patient starts across the category; 80%+ of relapsed/refractory category revenue remains in that setting.
Revuforj growth is supported by new starts, recurring revenue, longer treatment, transplant and post-transplant maintenance.
Niktimvo had more than 300 new patient starts and penetration above one-third in the third-line-plus market; fourth-line penetration is higher.
Revuforj expansion and clinical evidence
For KMT2A, about 50% of patients reached transplant and about 60% of those returned for maintenance; management sees potential to reach 60% and 70%–80%, respectively.
For NPM1, about 40% reached transplant and 50% of those returned for maintenance this quarter; management sees potential for 60%–70% to return for maintenance.
Treatment duration is about seven months for responding patients not transplanted and over nine months for patients on maintenance; physicians anticipate 1–2 years of maintenance, potentially longer.
EVOLVE and REVEAL frontline trials have hundreds of sites open; ASH updates will include phase I/II data, with further trial progress expected to be discussed in 2027.
ASH has 14 accepted abstracts, including seven oral presentations; BEAT AML VEN-AZA combination data show a 68% CR rate and 24-month median OS overall, while NPM1 median OS is not reached and 56% are alive at two years.
ASH research and treatment trends
AUGMENT data show 40% of patients proceeding to transplant lacked CR/CRh, including other morphological remissions; a phase I maintenance study will report tolerability, feasibility and MRD clearance through one to two years.
Nearly half of Revuforj use is off-label, primarily combinations with VEN-AZA, reflecting earlier treatment and physician interest in combination regimens.
The INTERCEPT study evaluates treatment at MRD recurrence; ASH data will include high rates of MRD eradication and MRD responses.
Latest events from Syndax Pharmaceuticals
- Maintenance growth and frontline trials support a new phase of pipeline expansion.SNDX
Stifel 2026 Healthcare Conference 2026 - Revenue rose 82% as Revuforj and Niktimvo grew and clinical programs advanced.SNDX
Q3 2026 - Strong commercial growth and pivotal trial catalysts highlight a transformative year ahead.SNDX
H.C. Wainwright 28th Annual Global Investment Conference - Dominant AML market share, advancing pivotal trials, and expanding pipeline in oncology and fibrosis.SNDX
Citigroup’s Biopharma Back to School Summit 2026 - Q2 2026 revenue surged 92% YoY, driven by Revuforj and Niktimvo growth and pipeline progress.SNDX
Q2 2026 - Expanding pipeline and late-stage programs drive growth and value across major indications.SNDX
R&D Day 2026 - Rapid sales growth and pipeline expansion position for multi-billion dollar market leadership.SNDX
H.C. Wainwright 27th Annual Global Investment Conference - Two product launches target multi-billion dollar markets with robust early adoption and expansion plans.SNDX
TD Cowen 45th Annual Healthcare Conference - FDA approves Niktimvo for refractory chronic GVHD, with U.S. launch expected by early Q1 2025.SNDX
FDA Announcement